Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.64 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | TYK2 | P29597 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.51 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.51 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.50 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1613960 | 0.82 | PTK2 (0.62) | LRRK2PTK2 | |
| SCHEMBL1612594 | 0.82 | LRRK2 (0.59) | LRRK2PTK2ALK | |
| SCHEMBL1611693 | 0.80 | LRRK2 (0.68) | LRRK2PTK2 | |
| SCHEMBL1612637 | 0.79 | PTK2 (0.66) | LRRK2PTK2 | |
| SCHEMBL12065489 | 0.78 | LRRK2 (1.00) | LRRK2PTK2 | |
| SCHEMBL2637120 | 0.76 | PTK2 (0.54) | LRRK2PTK2JAK2NTRK1TYK2 | |
| SCHEMBL2033017 | 0.76 | PTK2 (0.54) | LRRK2PTK2JAK2NTRK1TYK2 | |
| SCHEMBL24752696 | 0.76 | MAP4K1 (0.63) | LRRK2PTK2JAK2NTRK1TYK2 | |
| SCHEMBL5568353 | 0.76 | LRRK2 (0.53) | LRRK2PTK2JAK2NTRK1TYK2 | |
| SCHEMBL2033013 | 0.76 | PTK2 (0.51) | LRRK2PTK2JAK2NTRK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751118-B1 | PYRIMIDINES FOR USE AS PLK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-12-03 | — | — | EP | disclosed |
| EP-1751118-B1 | PYRIMIDINES FOR USE AS PLK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-12-03 | — | — | EP | disclosed |
| US-7241769-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-7241769-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-7241769-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-20050261295-A1 | 2-Anilino-4-amino-, -oxy- or -thio-substituted, e.g., 2-(2-methoxy-4-N-propylcarbamoyl-phenylamino)-4-(2-carboxy-3-fluoro-phenylamino)-5-trifluoromethyl-pyrimidine; and 3-anilino--5-amino-, -oxy- or -thio-substituted 1,2,4-triazines; antiproliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
| EP-1598343-A1 | 2-Arylaminopyrimidine derivatives as PLK inhibitors | Boehringer Ingelheim International GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261295-A1 | 2-Anilino-4-amino-, -oxy- or -thio-substituted, e.g., 2-(2-methoxy-4-N-propylcarbamoyl-phenylamino)-4-(2-carboxy-3-fluoro-phenylamino)-5-trifluoromethyl-pyrimidine; and 3-anilino--5-amino-, -oxy- or -thio-substituted 1,2,4-triazines; antiproliferative agents | MKI67, CCNY, CCNO | LRRK2 3385/4885PTK2 2484/4885JAK2 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.